MariMed Statement on Historic Rescheduling of Cannabis
Rhea-AI Summary
MariMed (CSE: MRMD / OTCQX: MRMD) issued a CEO statement on Dec. 18, 2025 responding to federal rescheduling of cannabis to Schedule III. The company called the move the "single greatest cannabis reform" and said it formally recognizes medical uses and lower abuse potential.
The statement says rescheduling will accelerate accredited medical research, expand consumer adoption as an alternative to opioids, and end the IRS Section 280E tax penalty for state-legal cannabis businesses—allowing compliant operators to be taxed like other consumer packaged goods sectors and, the company says, materially improve profitability and free cash flow.
Positive
- Removal of IRS Section 280E penalty for state-legal businesses
- Expected material improvement in profitability and free cash flow
- Rescheduling to Schedule III may accelerate accredited medical research
- Potential increase in consumers using cannabis as an alternative to opioids
Negative
- None.
News Market Reaction
On the day this news was published, MRMD declined 17.01%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NORWOOD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator committed to improving lives every day, issued the following statement from CEO Jon Levine today.
“We commend President Trump and the Trump Administration for reclassifying cannabis as a Schedule III drug. This is the single greatest cannabis reform in US history and will have far-reaching benefits for years to come. Most important, the reclassification means the Federal government officially acknowledges that cannabis has widely accepted medical uses and low abuse potential.
Rescheduling will accelerate accredited medical research into medications derived from cannabis and should result in a significant increase of consumers who will embrace cannabis as a qualified alternative to opioids for chronic pain, sleep, anxiety and other ailments.
Additionally, state-legal cannabis businesses will no longer be subject to the IRS Section 280E tax penalty. Compliant operators like MariMed will finally be taxed like other consumer packaged goods sectors, materially improving profitability and free cash flow.”
About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty's Eddies™, Bubby’s Baked™, Vibations™, InHouse™, and Nature’s Heritage™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.
Media Contact:
Zach Galasso
DPA Communications
Email: zach@dpacommunications.com
Phone: (978) 604-5423
Company Contact:
Howard Schacter
Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007
FAQ
What did MariMed (MRMD) announce on Dec. 18, 2025 about cannabis rescheduling?
How will the Schedule III rescheduling affect MariMed's (MRMD) taxes?
Does MariMed (MRMD) expect rescheduling to affect profitability?
Will MariMed (MRMD) see increased medical research after rescheduling?
What consumer impacts did MariMed (MRMD) highlight from rescheduling?
